Lang D M
Department of Medicine, Hahnemann University Hospital, Philadelphia, USA.
Drug Saf. 1995 May;12(5):299-304. doi: 10.2165/00002018-199512050-00002.
Studies have demonstrated greater hazards associated with anaphylaxis in patients receiving beta-blockers. Serious anaphylaxis is more frequent. Evidence suggests this occurs via modulation of adenylate cyclase, which can influence release of anaphylactogenic mediators. Treatment of anaphylaxis in patients exposed to beta-blockers is complicated because therapeutic administration of epinephrine (adrenaline) may be ineffective or promote undesired alpha-adrenergic and vagotonic effects. Risk reduction efforts should be considered for patients receiving beta-blockers who are prone to experience anaphylaxis.
研究表明,接受β受体阻滞剂治疗的患者发生过敏反应时的风险更高。严重过敏反应更为常见。有证据表明,这是通过调节腺苷酸环化酶发生的,而腺苷酸环化酶可影响过敏介质的释放。由于使用肾上腺素进行治疗可能无效或会产生不良的α肾上腺素能和迷走神经作用,因此,对使用β受体阻滞剂的患者进行过敏反应治疗较为复杂。对于容易发生过敏反应的使用β受体阻滞剂的患者,应考虑采取降低风险的措施。